View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


6th Annual DPharm Agenda Published

  • June 30, 2016

  • We are excited to announce the first draft of the agenda for the 6th Annual DPharm: Disruptive Innovations to Advance Clinical Trials is published.

    DPharm 2016 opens with artist Phil Hansen, who provides his perspective as a patient on turning a nearly tragic disability into an overflowing amount of creativity. To demonstrate innovative ways to transform patient engagement, examples from other industries are featured, including:

    • Formula One race car engineering company, McLaren
    • FitBit
    • Ochsner Healthcare system

    The 2016 agenda is packed with examples of progress in advancing clinical trials from Eli Lilly, Novartis, Pfizer, Janssen, Genentech and more will be added.

    Valerie Bowling at DPharm EuropeDPharm Executive Director, Valerie Bowling says, “This year’s event addresses tough questions on getting R&D to think like a service industry and to how to get the other 98% on board to make significant changes.”

    DPharm brings a new line-up of technology presenters for DPharm Idol, keynotes, plenary and break out sessions, “Where Are They Now”, and the “Today Show @ DPharm” with one-on-one interviews.

    Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

    Craig Lipset, Head of Clinical Innovation, R&D, Pfizer at DPharm Europe

    “Collaboration is critical to bringing innovation in clinical development, but it requires the right environment,” says Craig Lipset, Head of Clinical Innovation in Pfizer Global Product Development. “DPharm provides the ideal space for drug developers, patients, technologists, regulators and other partners who want to drive change. It creates an environment to share and connect, with new partnerships sparked there each year. Seeing peers leave DPharm with the ideas and tools to innovate in their organizations gives me optimism that we can reinvent drug development together.”

    A new section, DharmX, has been introduced to help stimulate fresh ideas, such as how to make it easy for physicians to be investigators. Also debuting is a session on the investor’s view on what they see as up-and-coming innovation for clinical trials, and two examples of open source clinical research from the Moonshot Cancer 2020 and Zika Virus.

    For more information on the conference, agenda and speakers click here.